Adjunctive perampanel for refractory partial-onset seizures
Randomized phase III study 304
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 19, 2011
- Accepted March 28, 2012
- First Published July 25, 2012.
Article Versions
- Previous version (July 25, 2012 - 13:03).
- You are viewing the most recent version of this article.
Author Disclosures
- Jacqueline A. French, MD,
- Gregory L. Krauss, MD,
- Victor Biton, MD,
- David Squillacote, MD,
- Haichen Yang, MD,
- Antonio Laurenza, MD,
- Dinesh Kumar, MS and
- Michael A. Rogawski, MD, PhD
- Jacqueline A. French, MD,
Epilepsy Therapy Project; Eisai; UCB; Upsher-Smith; Sepracor; Vertex
NONE
Paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards orgive lectures:; UCB; Eisai; Johnson and Johnson; Valeant; GlaxoSmithKline; Upsher- Smith; Pfizer; Novartis; Eli Lilly; Sepracor; Supernus; Vertex
Epilepsy Currents, Associate Editor, 2009-2011; Epileptic Disorders, Supplement Editor; Lancet Neurology, Editorial Board, 2010-present; Neurotherapeutics, Editorial Board, 2010-present; Neurology Today, Editorial Board, 2010-present
NONE
NONE
NONE
President, Epilepsy Study Consortium, that recieves money from multiple pharmaceutical companies. I consult for a number of companies, on behalf of the Epilepsy Study consortium. A fixed 25% of my NYU salary is paid by the study consortium, and some of this money may come from consulting fees. Companies involved include GlaxoSmith Kline, Pfizer, UCB, Johnson & Johnson, Cyberonics, Schwarz Pharma, Ortho-McNeil, Eisai, Jazz Pharmaceuticals, Ovation Pharmaceuticals, Endo Pharmaceuticals, Bial Pharmaceuticals, Neurovista, Valeant Pharmaceuticals, Icagen, Supernus, SK Pharmaceuticals, Taro Pharmaceuticals, Neurotherapeutics, Sepracor, Novartis, Pfizer, Upsher-Smith, Vertex
NONE
NONE
NONE
PI on clinical trials for; Johnson & Johnson; Eisai; UCB; SK; Valeant; Upsher-Smith; Vertex; Pfizer
NIH 1 R01 NS053998-01A1, Coinvestigator, 2007-2011
NONE
Epilepsy Research Foundation; The Milken Foundation Non-financial disclosures: President, Epilepsy Study Consortium
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory L. Krauss, MD,
Epilepsy Study Consortium, Vice President; Lundbeck vigabatrin visual safety monitoring board (SHARE)
NONE
Eisai Inc., airfare for presenting research at neurology meeting
Epilepsy Currents, clinical science editor, 2010-2011
NONE
The Johns Hopkins Digital EEG Atlas, JHU Press, 2006, 2011
NONE
Vertex Laboratories; 2) Eisai Inc.
NONE
NONE
NONE
UCB Pharma, Principal Investigator, 2009-Present; Eisai Lab, Principal Investigator, 2009-Present; Sepracor Inc., Principal Investigator, 2009-Present; Vertex Inc., Principal Investigator, 2010-2011; Novartis, Principal Investigator, 2011
NIA, RC2AG036419, Principal Investigator, 2009-Present
NONE
The Epilepsy Research Foundation, Co-Principal Investigator, 2009-Present
NONE
NONE
NONE
NONE
NONE
NONE
- Victor Biton, MD,
Dec 2010 - Eisai regarding E2007 Jan 2011 - Lundbeck regarding Clobazam June 2011 - Upsher-Smith
NONE
NONE
NONE
NONE
NONE
NONE
Dec 2010 - Eisai regarding E2007 Jan 2011 - Lundbeck regarding Clobazam June 2011 - Upsher-Smith
NONE
NONE
Clinical Trials, Inc. - Private Research facility/PI E2007-G000-304/307 (2008-2011) E2007-A01-206/207 (2005-2007)
Victor Biton, MD is currently an investigator for Eisai, Janssen, King, Medivation, Pfizer, Sepracor/Sunovion, UCB/Schwarz, Depomed, Lundbeck, Schering-Plough/Merck, Upsher-Smith, SK Life Sciences, Daiichi Sankyo, Vertex and Wyeth. Dr. Biton has been an investigator for Xenoport, Medivation, Dainippon, GSK, Genzyme, Astellas/Fujisawa, Myriad, RWJPRI, Insmed, Ortho McNeil, Jazz, Carter Wallace/MedPointe, Parke-Davis, HMR/Sanofi-Aventis, Novartis, IVAX, Abbott, AstraZeneca, Cyberonics, , Schwabe, SkyePharma, NPS, Saegis, Eunoe, Genentech, Abbott, J&J, Marinus, Intranasal/Ikano, Ovation/Lundbeck, Schwarz/UCB, Valeant, XTL, Forest, Elan, Icagen, Impax and Vernalis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Squillacote, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Eisai Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Haichen Yang, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Eisai Inc., Senior Director
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antonio Laurenza, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Eisai, Inc., Executive Director, Clinical Development
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dinesh Kumar, MS and
NONE
NONE
NONE
NONE
NONE
NONE
Employed by Eisai Inc
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael A. Rogawski, MD, PhD
Gilead Sciences Novartis Pharma Teva Pharmaceuticals
NONE
GlaxoSmithKline UCB
BMC Pharmacology, editorial board, 2001–present Cellular and Molecular Neurobiology, editorial board, 1988–present Molecular Pharmacology, editorial advisory board, 1994– present Neurotherapeutics, associate editor, 2005-present Scientific Reports, editorial board, 2011–present The Open Pharmacology Journal, editorial advisory board, 2008–present The Scientific World Journal: Pharmacology Domain, editorial board, 2011–present
Treatment for epilepsy; Formulation of neurosteroids
NONE
NONE
Eisai Eli Lilly & Co. Ono Pharmaceuticals USA Sepracor SK Life Sciences Upsher-Smith
NONE
NONE
NONE
Eisai Gilead Sciences
Congressionally Directed Medical Research Programs, DR081314, principal investigator, 2009-present Congressionally Directed Medical Research Programs, DR081314, co-principal investigator, 2011-present National Institutes of Health, NS072094, principal investigator, 2010-present National Institutes of Health, RR024146, principal investigator, 2012
NONE
Epilepsy Research Foundation People Against Childhood Epilepsy
NONE
NONE
NONE
Marinus Pharmaceuticals, 2004 MedGenesis Therapeutix, 2008
NONE
NONE
- From the NYU Comprehensive Epilepsy Center (J.A.F.), New York, NY; Johns Hopkins University (G.L.K.), Baltimore, MD; Arkansas Epilepsy Program (V.B.), Little Rock; Eisai Inc. (D.S., H.Y., A.L., D.K.), Woodcliff Lake, NJ; and Department of Neurology (M.A.R.), School of Medicine and Center for Neuroscience, University of California, Sacramento.
- Hospital General de Agudos Dr. Jose Maria Ramos Mejia, Ciudad Autonoma de Buenos Aires, Principal Investigator
- Fundación Para la Lucha Contra lasEnfermedadesNeurológicas de la Infancia, Capital Federal, Principal Investigator
- InstitutoGinecologico Lanus Oeste, Buenos Aires IGBA, Lanus Oeste, Buenos Aires, Principal Investigator
- Hospital y Clinica OCA, SociedadAnónima de Capital Variable, Monterrey, Nuevo León, Principal Investigator
- Correspondence & reprint requests to Dr. French: Jacqueline.French{at}nyumc.org
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.